journal article·2019-08-07

Resolution of Baclofenium Hydrogenomaleate By Using Preferential Crystallization. A First Case of Complete Solid Solution at High Temperature and a Large Miscibility Gap in the Solid State

François-Xavier Gendron, Julien Mahieux, Morgane Sanselme, Gérard Coquerel

Crystal Growth & Design· Volume 19· Issue 8
Publisher page

Abstract

The (R)- and (S)-baclofenium hydrogenomaleate system exhibits an extensive chiral discrimination in the solid state at room temperature. Nevertheless, above 145 °C, the critical temperature, a complete solid solution between the two enantiomers is stable. The 50–50 mixture does not form any racemic compound at any temperature, and at 20 °C, the two mirror phases show limited symmetrical solid solutions as the enantiomeric excess equals 98.5%. This is due to a large miscibility gap in the solid state. Close to room temperature, the racemic mixture can be resolved by preferential crystallization. The yield of the process can be enhanced in acidic aqueous solutions (e.g., in HCl aq 2 M), which increases the solubility.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Molecular spectroscopy and chirality · Crystallization and Solubility Studies · Crystallography and molecular interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratoire SMS EA3222, Normandie Université, 76821 Mont-Saint-Aignan Cedex, France

References (59)

Show source-provided references
1. 10.1016/j.ejphar.2006.08.06810.1016/j.ejphar.2006.08.068 ↗
2. 10.1177/08830738960110020210.1177/088307389601100202 ↗
3. 10.1002/ana.41015030610.1002/ana.410150306 ↗
4. 10.2165/00002018-200427110-0000410.2165/00002018-200427110-00004 ↗
5. 10.1186/1471-244X-3-1610.1186/1471-244X-3-16 ↗
6. 10.1097/FBP.0b013e328357bd6210.1097/FBP.0b013e328357bd62 ↗
7. 10.1093/alcalc/37.5.50410.1093/alcalc/37.5.504 ↗
8. Jaques J. · 1994 · 86
9. 10.1007/BF0054192210.1007/BF00541922 ↗
10. 10.1139/v94-29410.1139/v94-294 ↗
11. 10.1016/S0957-4166(00)82107-210.1016/S0957-4166(00)82107-2 ↗
12. 10.1016/S0040-4039(03)01278-410.1016/S0040-4039(03)01278-4 ↗
13. 10.1016/S0040-4039(02)01449-110.1016/S0040-4039(02)01449-1 ↗
14. 10.1039/a606037d10.1039/a606037d ↗
15. Gernez D. · C. R. Acad. Sci. · 1866 · 63 · 843
16. 10.1021/cr60223a00610.1021/cr60223a006 ↗
17. 10.1021/cr60325a00110.1021/cr60325a001 ↗
18. 10.1007/128_2006_07710.1007/128_2006_077 ↗
19. Coquerel, G.; Petit, M.N.; Bouaziz, R. Procede De Dedoublement De Deux Antipodes Optiques Par Cristallisation. WO/1995/008522, March 31, 1995.
20. 10.1039/c001895c10.1039/c001895c ↗
21. Coquerel, G.; Levilain, G. Process for the Resolution of Enantiomers by Preferential Evaporative Crystallization. WO2011/073300, December 16, 2010.
22. 10.1021/cg400589u10.1021/cg400589u ↗
23. 10.1021/acs.oprd.5b0014110.1021/acs.oprd.5b00141 ↗
24. 10.1021/cg501854g10.1021/cg501854g ↗
25. 10.1002/aic.1493410.1002/aic.14934 ↗
26. 10.1021/op100173r10.1021/op100173r ↗
27. 10.1016/S0009-2509(00)00442-510.1016/S0009-2509(00)00442-5 ↗
28. 10.1039/b100706h10.1039/b100706h ↗
29. 10.1021/op030022g10.1021/op030022g ↗
30. 10.1039/C1CE05484H10.1039/C1CE05484H ↗
31. 10.1016/j.tetasy.2010.07.01910.1016/j.tetasy.2010.07.019 ↗
32. 10.1021/cg300994310.1021/cg3009943 ↗
33. 10.1002/chir.2006710.1002/chir.20067 ↗
34. 10.1021/cg070075f10.1021/cg070075f ↗
35. 10.1016/j.tetasy.2007.03.01110.1016/j.tetasy.2007.03.011 ↗
36. 10.1021/op200092f10.1021/op200092f ↗
37. Florey K. · 1972 · 22
38. 10.1107/S002188987601078910.1107/S0021889876010789 ↗
39. 10.1021/cg801356m10.1021/cg801356m ↗
40. 10.1002/ceat.20140075610.1002/ceat.201400756 ↗
41. 10.1002/14356007.a16_05310.1002/14356007.a16_053 ↗
42. Rowe R. C. · 2009
43. SMART for WNT/2000 V5. 622, Smart software reference manual; Bruker Advanced X Ray Solutions, Inc.: Madison, WI, 2001.
44. SAINT+ V6. 02; Saint software reference manual; Bruker Advanced X Ray Solutions, Inc.: Madison, WI, 1999.
45. 10.1107/S010876739000027710.1107/S0108767390000277 ↗
46. Sheldrick G. M. · 1997
47. Farrugia L. J. · 1999
48. 10.1016/S0039-9140(03)00352-710.1016/S0039-9140(03)00352-7 ↗
49. 10.1107/S010876810905361010.1107/S0108768109053610 ↗
50. 10.1039/C5CE01383F10.1039/C5CE01383F ↗
51. Ricci J. E. · 1966
52. 10.2174/138161282266616072016423010.2174/1381612822666160720164230 ↗
53. Coquerel G. · Enantiomer · 2000 · 5 · 481
54. 10.1016/0040-6031(95)02716-510.1016/0040-6031(95)02716-5 ↗
55. 10.1016/0040-6031(95)02717-310.1016/0040-6031(95)02717-3 ↗
56. 10.1016/0040-6031(96)02964-410.1016/0040-6031(96)02964-4 ↗
57. 10.1016/S0040-6031(98)00579-610.1016/S0040-6031(98)00579-6 ↗
58. 10.1107/S010876819700290510.1107/S0108768197002905 ↗
59. Miki, T.; Takeda, M.; Yamazaki, T. Optically Active 4-Amino-3-(4-Chlorophenyl)Butanoic Acid. US8669395B2, March 11, 2014.